Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Edwards Lifesciences : Oppenheimer Adjusts Edwards Lifesciences PT to $120 From $97 on Strong Q2 Results & Raised 2021 Guidance, Maintains Outperform Rating

07/30/2021 | 12:28pm EST


ę MT Newswires 2021
All news about EDWARDS LIFESCIENCES CORPORATION
12/08Edwards Lifesciences Issues Fiscal 2022 Guidance, Reaffirms 2021 Outlook
MT
12/08Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
PR
12/07NORTH AMERICAN MORNING BRIEFING : Dow Futures Jump -3-
DJ
12/06WALL STREET STOCK EXCHANGE : Wall Street bounces back
12/06ANALYST RECOMMENDATIONS : Apple, Boston Beer, Goldman Sachs, Steven Madden, Synthomer...
12/06Wells Fargo Upgrades Edwards Lifesciences to Overweight From Equalweight; Price Target ..
MT
11/24INSIDER BUY : Edwards Lifesciences
MT
11/22INSIDER SELL : Edwards Lifesciences
MT
11/10INSIDER SELL : Edwards Lifesciences
MT
11/08INSIDER SELL : Edwards Lifesciences
MT
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 5 257 M - -
Net income 2021 1 431 M - -
Net cash 2021 1 325 M - -
P/E ratio 2021 51,9x
Yield 2021 -
Capitalization 74 583 M 74 583 M -
EV / Sales 2021 13,9x
EV / Sales 2022 12,4x
Nbr of Employees 14 900
Free-Float 96,6%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 119,46 $
Average target price 122,75 $
Spread / Average Target 2,75%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors